Germany’s Boehringer Ingelheim has selected a third drug candidate to move forward into IND-enabling studies under its ongoing collaboration with Oxford BioTherapeutics.

Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

Analysts have recently evaluated Elanco Animal Health and provided 12-month price targets. The average target is $15.25, ...

Guidelines aimed at increasing transparency about how the regulator will evaluate pharmaceutical pricing, official says ...

The real-world evidence solutions market is largely driven by the increasing prevalence of chronic diseases and their impact on real-world healthcare ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

Boehringer Ingelheim has launched Vetmedin (pimobendan) 1.5 mg/ml oral solution for dogs in the UK, offering a new treatment ...

Sonelokimab, adalimumab, lutikizumab, and bimekizumab are the top-rated treatments for moderate-to-severe HS, a network ...

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...

Weber Shandwick MENAT has launched the second edition of InfluAnswer Arabia, a report informed by the perspectives of cont ...

Today, on World Bronchiectasis Day, the American Lung Association is launching a new campaign to support people living with ...

Rinri Therapeutics, a world leading spinout company from the University of Sheffield dedicated to transforming sensorineural ...